Moreover, the prognosis of BC patients with ER+Her2‐ PM tumors is significantly worse than that of patients with ‘conventional’ wtp53 tumors, and similar to that of patients with authentic mut TP53 tumors, as assessed by overall survival (Fig. 5B) and distant relapse‐free survival (Fig. S9A). The gene discussed is TP53; the disease is breast cancer.